Identification of High-Mobility Group Box 1 (HMGB1) Expression as a Potential Predictor of Rejection and Poor Prognosis After Liver Transplantation

ABEF 1,2 Zhou Ye
FG 1,2 Junjun Jia
BCF 1,2 Zhen Lv
AG 1,2 Shusen Zheng

Background: Acute cellular rejection (ACR) frequently occurs after liver transplantation (LT) and can result in permanent damage of the liver allograft. Specific and sensitive biomarkers for predicting and monitoring ACR are vital for guiding post-transplantation care. In the present study, we aimed to investigate the function of high-mobility group box 1 (HMGB1) in predicting ACR and prognosis after LT.

Material/Methods: A total of 113 LT recipients were enrolled in the study, including 62 patients in an ACR group and 51 patients in a non-rejection group. Using tissues from the 113 patients, HMGB1 expression was examined by immunohistochemistry, and the total score for HMGB1 expression was calculated by multiplying the percentage of immunoreactive cells score and the staining intensity score. We then analyzed the association between HMGB1 expression and clinical features. Finally, the function of HMGB1 in predicting the prognosis of LT was determined using Kaplan-Meier (K-M) survival and Cox multivariate analyses.

Results: Immunohistochemical staining results demonstrated that the expression of HMGB1 was significantly increased in the ACR group, compared with that in the non-rejection group (P<0.05). Clinical characteristic analysis revealed that high HMGB1 levels were related to ACR (P<0.05). Moreover, K-M survival analysis showed that patients with high HMGB1 expression displayed poorer prognosis (P<0.05). Cox multivariate analysis demonstrated that HMGB1 was an independent prognostic predictor for post-LT survival (odds ratio, 3.283; P=0.008).

Conclusions: LT recipients’ HMGB1 levels may be a useful and noninvasive biomarker for the prediction of ACR and prognosis after LT.

Keywords: Graft Rejection • High Mobility Group Proteins • Immunity, Innate • Liver Transplantation

Full-text PDF: https://www.annalsoftransplantation.com/abstract/index/idArt/931625
Background

Acute cellular rejection (ACR) is a common cause of liver insufficiency after liver transplantation (LT), with an incidence of 30% to 70%, and can lead to transplant failure [1,2]. Although LT is valid for treating end-stage liver disease, ACR remains a significant post-transplant complication [3]. ACR causes infection and cancer recurrence in recipients due to the increased use of immunosuppressants [4]. To avoid the increased use of immunosuppressive agents, accurate biomarkers are necessary to predict and identify the risk of ACR early [5,6]. Liver histopathology is the criterion standard for the diagnosis of graft dysfunction after LT via liver biopsy. Expert LT pathologists are required to obtain accurate pathological results [7]. Laboratory tests are also used to examine allograft rejection, but the specificity and sensitivity of these laboratory indexes are not sufficient [8]. Therefore, it is essential to explore specific and noninvasive prognostic markers that can monitor the risk of ACR and be useful in treating transplant rejection.

High-mobility group box 1 (HMGB1) exerts a proinflammatory cytokine-like function by binding DNA and regulating transcription. HMGB1 is generated during systemic disorders and serves as an alarm signal to initiate an inflammatory reaction [9-11]. Accumulating evidence shows that HMGB1 is a vital early participant in liver, kidney, and heart injury and inflammation after ischemia-reperfusion (I/R) [12-14]. In a liver I/R mouse model, increased HMGB1 expression was found in the early stage of reperfusion, and the application of an extracellular HMGB1-neutralizing antibody exerted an obvious protective effect on liver injury after I/R [15]. The absence of hepatocyte-specific HMGB1 aggravates liver I/R injury and inflammation, which is at least partly due to enhanced DNA injury and nuclear instability, thereby increasing histone release [16].

Moreover, anti-histone H1/HMGB1 antibodies have been shown to play an immunosuppressive role [17,18], and a previous study demonstrated that blocking extracellular HMGB1 can significantly prolong the survival rate of transplanted hearts in mice [19]. These results suggest that HMGB1 may play a pro-injury and inflammatory role in transplantation. However, the function of HMGB1 in ACR after LT has not been fully elucidated.

In the present study, we focused on evaluating the association between HMGB1 and the incidence of post-LT ACR in a group of 113 patients with LT. For this purpose, the expression of HMGB1 was examined in the recipient liver samples by immunohistochemistry, and the incidence of ACR in the first 2 years after LT was recorded and analyzed.

Material and Methods

Patients and Samples

The study enrolled 113 patients who received LT at the First Affiliated Hospital of Zhejiang University (Hangzhou, China) between 2006 and 2014, including 62 patients with ACR (rejection group) and 51 patients without ACR (non-rejection group). All recipients were diagnosed with end-stage liver disease caused by benign hepatic disease. Liver specimens were removed and paraffin-embedded for further study. The immunosuppressive scheme received by all patients was tacrolimus-based, including corticosteroids and mycophenolate mofetil. All ACR diagnoses were based on clinically increased liver transaminase levels and pathological evaluations by needle core liver biopsies, which were independently confirmed by 2 expert pathologists. The study was approved by the Ethics Review Committee of the First Affiliated Hospital of Zhejiang University, which abided by the Helsinki Declaration on ethical principles. Written informed consent was obtained from all patients.

Tissue Microarray and Immunohistochemical Staining

The level of HMGB1 in the liver tissues of the 113 patients was detected by tissue microarray (TMA) using formalin-fixed paraffin sections. We placed the tissue samples on the TMA blindly to avoid bias in the immunohistochemical (IHC) staining results. To avoid tissue loss and tissue heterogeneity, each sample was placed in triplicate, and 2 experts conducted semi-quantitative scoring of the staining intensity and percentage of immunoreactive cells, without any knowledge of patient information. Staining intensity was divided into 3 levels: “0” for weak staining, “1” for moderate staining, and “2” for strong staining. For the percentage of immunoreactive cells, we defined “0” as <20% positivity, “1” as 21% to 40%, “2” as 41% to 60%, “3” as 61% to 80%, and “4” as 81% to 100%. The percentage of immunoreactive cells multiplied by the staining intensity score was used to calculate the total expression score of HMGB1. The total score ranged between 0 and 8. We defined a high HMGB1 expression score as ≥4.

Statistical Analysis

Statistical analysis was performed using SPSS version 18.0 (Chicago, IL, USA). The number, mean±standard deviation, or median±interquartile range was used to present the data. Categorical variables were analyzed using Fisher’s exact test. The relationship between HMGB1 expression levels and clinical outcomes was assessed using the chi-squared test by analyzing the IHC staining results. The Kaplan-Meier (K-M) method was used to analyze overall survival, and survival differences were determined using the log-rank test. The Cox regression model was used for multivariate analysis. A P value <0.05
was considered statistically significant, with a confidence interval of 95%.

Results

HMGB1 Expression in the Livers of Patients with ACR

To validate our hypothesis that the LT recipient HMGB1 expression levels were related to post-transplant ACR, we first examined the expression of HMGB1 in the 113 patient tissues, including those of the 62 patients with ACR and 51 patients without ACR. The demographic and clinical features of the patients are presented in Table 1. No differences were found in age, sex, donor age, cause of disease, model for end-stage liver disease (MELD) scores, Child-Pugh scores, serum creatinine concentration, and ABO compatibility between the 2 groups. HMGB1 expression in the 2 groups was examined by IHC staining in a tissue microarray. The results indicated that HMGB1 expression levels were significantly higher in the rejection group ($P < 0.05$; Figure 1).

Correlation of HMGB1 Expression with Recipient Survival and ACR

Based on the expression of HMGB1 in recipient liver tissues, we divided the patients into a high-expression group (n=38; IHC staining score $\geq 4$) and a low-expression group (n=75; IHC staining score $<4$). No differences in age, sex, MELD scores, and Child-Pugh scores were observed (Table 2). However, HMGB1 expression was clearly related to ACR ($P = 0.039$). Moreover, K-M survival analysis showed that the survival of patients with low HMGB1 levels was improved, compared with that of patients with high HMGB1 levels ($P < 0.05$; Figure 2).

Validation of HMGB1 Levels as a Potential Prognostic Factor in Patients with LT

To confirm that HMGB1 expression level was a prognostic marker for LT, we used a Cox regression model to examine whether patient HMGB1 expression was an independent prognostic factor. Our results suggested that female sex was a protective prognostic factor (hazard ratio [HR], 0.111; $P < 0.05$) (Table 3). Notably, HMGB1 expression level was clearly related to poor overall survival (odds ratio [OR], 3.283; $P < 0.05$), indicating that a high HMGB1 level may be an independent and adverse prognostic marker in LT recipients.

Discussion

ACR is one of the principal reasons for graft dysfunction after LT [20]. Liver biopsy is still the most accurate method for ACR diagnosis, but noninvasive and sensitive biomarkers remain necessary owing to the cost, inconvenience, and invasiveness of liver biopsy [21]. In the present study, we demonstrated that HMGB1 overexpression was present in LT recipients with ACR. We also found the main cause of death in the high-expression HMGB1 group was loss of transplanted liver function, followed by death due to abdominal bleeding, infection, biliary tract complications, and other causes due to liver failure during follow-up. However, the main cause of death in the low-expression HMGB1 group was primary disease, followed

### Table 1. Demographic and clinical characteristics of liver transplant patients.

| Characteristics, n (%) | Rejection (n=62) | Non-rejection (n=51) | P value |
|------------------------|-----------------|---------------------|---------|
| Age                    | 42.7±9.88       | 42.5±9.78           | NS      |
| Sex                    |                 |                     |         |
| Male                   | 50              | 45                  | NS      |
| Female                 | 12              | 6                   |         |
| Donor age              |                 |                     |         |
| 32.1±11.58             | 30.3±10.21      | NS                  |
| Primary diagnosis      |                 |                     |         |
| HBV cirrhosis          | 53              | 39                  | NS      |
| Other                  | 9               | 12                  |         |
| MELD scores            |                 |                     |         |
| 23.6±10.29             | 23.9±10.22      | NS                  |
| Child-Pugh scores      |                 |                     |         |
| 10.0±2.21              | 10.0±2.15       | NS                  |
| Serum creatinine (µmol/L) |           |                     |         |
| 99.5±112.17            | 101.7±114.23    | NS                  |
| ABO compatible (%)     |                 |                     |         |
| Compatible             | 51              | 41                  | NS      |
| Incompatible           | 11              | 10                  |         |

NS – no significance ($P>0.05$); HBV – hepatitis B virus; MELD – model for end-stage liver disease.
Figure 1. High-mobility group box 1 (HMGB1) expression in resected recipient livers. (A) Typical immunohistochemical (IHC) staining results were obtained from the rejection group. (B) Typical IHC staining results were obtained from the non-rejection group. (C) HMGB1 expression levels in the 2 groups. The data are expressed as means±standard deviations. * P<0.05 vs the rejection group.

Table 2. Characteristics of recipients between the HMGB1 high-expression group and low-expression group.

| HMGB1 expression level | High expression (n=38) | Low expression (n=75) | P value |
|------------------------|------------------------|-----------------------|---------|
| Age                    | 42.6±9.89              | 43.2±9.93             | NS      |
| Sex (Male/Female)      | 34/4                   | 61/14                 | NS      |
| Child-Pugh scores      | 10.0±2.17              | 9.7±2.10              | NS      |
| MELD scores            | 23.6±10.27             | 21.7±9.50             | NS      |
| Rejection (n)          | 26                     | 36                    | 0.039   |
| Non-rejection (n)      | 12                     | 39                    |         |

NS – no significance; HMGB1 – high-mobility group box 1; MELD – model for end-stage liver disease.
by progressive loss of liver function caused by chronic rejection, cardiovascular disease, and other causes. Our results suggested that HMGB1 level was an independent predictor of patient prognosis and HMGB1 can be used as a new biomarker for liver ACR prediction and monitoring.

HMGB1 is a DNA-binding protein expressed in almost all eukaryotic cells, which can stabilize the formation of nucleosomes and promote transcription as a nuclear factor [22]. Recent studies have shown that HMGB1 plays vital roles in response to tissue injury, suggesting that HMGB1 is a new molecular prototype of a damage-related molecular model [23,24]. During infection and inflammatory stimuli, HMGB1 is released by activated immune cells, such as macrophages [25], dendritic cells [26], and natural killer cells [27]. The secreted HMGB1 then leads to an inflammatory reaction via cellular signal transduction mediated by its receptors, such as Toll-like receptor (TLR)2, TLR4 [28,29], and advanced glycation end products [29,30]. Moreover, HMGB1 levels are clearly augmented during severe sepsis in humans and animals, and death from sepsis can be prevented by specific HMGB1-neutralizing antibodies [31]. Ilmakunnas et al demonstrated that HMGB1 was exclusively released from the graft and that its levels correlated with postoperative alanine aminotransferase levels in 20 LT recipients [32]. These studies demonstrated that HMGB1 is an essential inducer of organ injury; however, its precise function in ACR is poorly understood. Here, we investigated the relationship between HMGB1 levels and ACR in LT recipients. We found that HMGB1 levels were higher in LT recipients with ACR and high HMGB1 levels were related to an increased incidence of ACR. Moreover, univariate and multivariate analyses indicated that high HMGB1 levels were correlated with poor prognosis. Thus, our study suggested that HMGB1 in the recipient liver is a predictive biomarker of ACR and prognosis after LT.

However, there are some limitations to this study. First, the data were retrospectively acquired. Second, the immune interactions of the recipient and the donor liver lead to ACR; however, we examined only recipient HMGB1 levels, ignored the level of HMGB1 in the patients’ serum, and the effect of donor HMGB1 levels remains unclear. Third, we failed to include some important information indicators in our study that can impact the prognosis of liver transplantation, such as donor-specific antibodies, trough level of immunosuppressive drugs, postoperative infection, and bacteremia. Finally, there was an insufficient number of enrolled samples, which may have caused some inconsistent results. For example, ABO incompatibility was not verified as an independent risk factor for rejection or prognosis.

Conclusions

The results of this study provide a strong theoretical basis for verifying whether HMGB1 expression level in LT recipients can be a useful noninvasive biomarker for predicting rejection and prognosis after LT in prospective trials.

Table 3. Multivariate analyses of overall survival in all recipient populations.

| Variables                             | B     | S.E.  | Wald  | df  | Sig. | Exp(B) |
|---------------------------------------|-------|-------|-------|-----|------|--------|
| Sex (Female vs Male)                  | -2.020| 0.597 | 13.59 | 1   | 0.000| 0.111  |
| Age, years (>50 vs ≤50)               | 0.420 | 0.630 | 0.444 | 1   | 0.505| 1.521  |
| Donor age (>40 vs ≤40)                | 0.362 | 0.559 | 0.401 | 1   | 0.656| 1.378  |
| MELD scores (≤22 vs >22)              | 0.026 | 0.727 | 0.001 | 1   | 0.972| 1.026  |
| Child-Pugh status (Child C vs Child A and B) | -1.476| 0.849 | 3.019 | 1   | 0.082| 0.229  |
| HMGB1 expression (high vs low)        | 1.189 | 0.679 | 3.067 | 1   | 0.008| 3.283  |

HMGB1 – high-mobility group box 1; MELD – model for end-stage liver disease.
Conflicts of Interest
None.

References:

1. Mor E, Solomon H, Gibbs JF, et al. Acute cellular rejection following liver transplantation: clinical pathologic features and effect on outcome. Semin Liver Dis. 1992;12:28-40
2. Fisher LR, Henley KS, Lucey MR. Acute cellular rejection after liver transplantation: Variability, morbidity, and mortality. Liver Transpl Surg. 1995;1:10-15
3. Florman S, Schiano T, Kim L, et al. The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation. Clin Transplant. 2004;18:152-55
4. Lai Q, Lesani S, Finkelstedt E, et al. Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: A multicenter European experience. Hepatobiliary Pancreat Dis Int. 2019;18:517-24
5. Choudhary NS, Saigal S, Bansal RK, et al. Acute and chronic rejection after liver transplantation: What a clinician needs to know. J Clin Exp Hepatol. 2017;7:358-66
6. Fenkel JM, Halagea DeMarzio DL. Management of the liver transplant recipient: Approach to allograft dysfunction. Med Clin North Am. 2016;100:477-86
7. Kumar S, Mohapatra N, Borle DP, Choudhury A, et al. Non invasive diagnosis of acute cellular rejection after liver transplantation – current opinion. Transpl Immunol. 2018;47:1-9
8. Okubo K, Wada H, Tanaka A, et al. Identification of novel and noninvasive biomarkers of acute cellular rejection after liver transplantation by protein microarray. Transplant Direct. 2016;2:e118
9. Sims GP, Rowe DC, Riedtjik ST, et al. HMGB1 and RAGE in inflammation and cancer. Ann Rev Immunol. 2010;28:367-88
10. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Ann Rev Immunol. 2011;29:139-62
11. Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets. 2018;22:263-77
12. Zhao G, Fu C, Wang L, et al. Down-regulation of nuclear HMGB1 reduces ischemia-induced HMGB1 translocation and release and protects against liver ischemia-reperfusion injury. Sci Rep. 2017;7:46272
13. Zhang J, Xia J, Zhang Y, et al. HMGB1-TLR4 signaling participates in renal ischemia reperfusion injury and could be attenuated by dexamethasone-mediated inhibition of the ERK/NF-kappaB pathway. Am J Transplant Res. 2016;8:4054-67
14. Xue J, Ge H, Lin Z, et al. The role of dendritic cells regulated by HMGB1/TLR4 signalling pathway in myocardial ischaemia reperfusion injury. J Cell Mol Med. 2019;23:2849-62
15. Tsung A, Sahal R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005;201:1135-43
16. Huang H, Nace GW, McDonald KA, et al. Hepatocyte-specific high-mobility group box 1 deletion worsens the injury in liver ischemia/reperfusion: A role for intracellular high-mobility group box 1 in cellular protection. Hepatology. 2014;59:1984-97
17. Nakano T, Kawamoto S, Lai CY, et al. Liver transplantation-induced antihistone H1 autoantibodies suppress mixed lymphocyte reaction. Transplantation. 2004;77:1595-603
18. Nakano T, Goto S, Lai CY, et al. Involvement of autoimmunity against nuclear histone H1 in liver transplantation tolerance. Transpl Immunol. 2008;19:87-92
19. Li JH, Zhao B, Zhu CX, et al. Blockade of extracellular HMGB1 suppresses xenoreactive B cell responses and delays acute vascular xenogeneic rejection. Am J Transplant. 2015;15:2062-74
20. Rook M, Rand E. Predictors of long-term outcome after liver transplant. Curr Opin Organ Transplant. 2011;16:499-504
21. Rodriguez-Peralvarez M, Rico-Juri JM, Toschatzis E, et al. Bispopy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: A systematic review and critical appraisal. Transpl Int. 2016;29:961-73
22. Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Immunol. 2004;255:332-42
23. Seong SY, Matzinger P. Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469-78
24. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331-42
25. Wang H, Bloom O, Zhang M, et al. HMGB-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-51
26. Dumitrutie I, Barauph P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 2005;174:7506-15
27. Semino C, Angelini G, Poggi A, Rubartelli A. NK/DC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood. 2005;106:609-16
28. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279:7370-77
29. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 2006;290:C917-24
30. Wang M, Wang L, Guo Y, et al. A high mobility group box 1 (HMGB1) gene from Chlamydia farrelli and the DNA-binding ability and pro-inflammatory activity of its recombinant protein. Fish Shellfish Immunol. 2014;36:393-400
31. Abdulmahdi W, Patel D, Rabadi MM, et al. HMGB1 mediates hepatic ischemia-reperfusion injury by a nuclear factor of activated T cells-mediated mechanism. Transpl Immunol. 2008;19:87-92
32. Ilmakunnas M, Tukiainen EM, Rouhiainen A, et al. High mobility group box 1 redox during sepsis. Fish Shellfish Immunol. 2014;36:393-400
33. Park JS, Smith RM, He Q, et al. Involvement of toll-like receptor 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279:7370-77
34. Seong SY, Matzinger P. Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469-78
35. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331-42
36. Wang H, Bloom O, Zhang M, et al. HMGB-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-51
37. Dumitrutie I, Barauph P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 2005;174:7506-15
38. Semino C, Angelini G, Poggi A, Rubartelli A. NK/DC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood. 2005;106:609-16
39. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279:7370-77
40. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 2006;290:C917-24
41. Wang M, Wang L, Guo Y, et al. A high mobility group box 1 (HMGB1) gene from Chlamydia farrelli and the DNA-binding ability and pro-inflammatory activity of its recombinant protein. Fish Shellfish Immunol. 2014;36:393-400
42. Abdulmahdi W, Patel D, Rabadi MM, et al. HMGB1 mediates hepatic ischemia-reperfusion injury by a nuclear factor of activated T cells-mediated mechanism. Transpl Immunol. 2008;19:87-92
43. Ilmakunnas M, Tukiainen EM, Rouhiainen A, et al. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 2008;14:1517-25

Declaration of Figures Authenticity
All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.